Elysium Health, a US-based provider of a new category of scientifically validated dietary supplements, has launched an advanced daily supplement called BASIS to target metabolic repair and optimization.

BASIS has been developed to support metabolic and cellular health, improve biological functions such as muscle repair and inflammatory response, and promote healthy aging with memory and cardiovascular health.

The first of the company’s upcoming line of dietary supplements, BASIS contains two new compounds.

Nicotinamide riboside, the first compound, is a precursor of the critical coenzyme NAD+, which is involved in metabolic processes such as energy production, DNA repair, cellular detoxification, the inflammatory response, and protein folding.

BASIS’s second component is a new polyphenol compound pterostilbene, which, like the NAD+ precursor, promotes metabolic health.

Elysium Health co-founder and chief scientist Dr Leonard Guarente said: "Recent technological innovations, combined with advancements in our understanding of basic biological mechanisms, finally give us this opportunity to develop novel products that may provide a meaningful impact on individuals’ health.

"We are thrilled to introduce BASIS and excited about Elysium’s potential to build upon the scientific understanding of how natural compounds can enhance an array of key biological functions, and then translate that knowledge into products that may help people improve and sustain their health."

Both compounds included in BASIS have been validated in several laboratories and been shown to improve metabolic health in scientific studies.

The company researches, develops, licenses and markets supplements that target biological deficiencies through new pathways that complement diet and exercise.